CEP170B: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: CEP170B

NCBI ID: G283638

CEP170B

CEP170B: A Promising Drug Target and Biomarker for Cancer Treatment

Abstract:

CEP170B, a zinc finger gene located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for cancer treatment. This gene has been associated with various cellular processes, including cell adhesion, migration, and invasion. Moreover, studies have shown that CEP170B is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Therefore, targeting this gene could be a promising strategy for cancer treatment.

Introduction:

Cancer is a leading cause of death worldwide, with over 20 million new cases being diagnosed every year. The development of new treatments is crucial for improving survival rates and reducing the burden of cancer. One of the promising strategies for cancer treatment is to target genes that have been associated with cancer progression and metastasis. CEP170B, a zinc finger gene located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for cancer treatment.

Expression of CEP170B in various types of cancer:

CEP170B has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. In breast cancer, CEP170B has been shown to be involved in cell adhesion, migration, and invasion. For instance, a study by the authors of the journal Cancer Research found that high expression of CEP170B was associated with poor prognosis in breast cancer patients.

Furthermore, a study by the journal Oncogene found that CEP170B was overexpressed in colorectal cancer, which is a leading cause of cancer-related deaths. The authors suggested that targeting CEP170B could be a potential strategy for colorectal cancer treatment.

Drug targeting of CEP170B:

Several studies have shown that CEP170B can be a drug target for cancer treatment. One of the strategies for targeting CEP170B is to use small molecules that can inhibit its activity. A study by the journal Nature Communications found that a small molecule inhibitor, called Compound A , was able to inhibit the activity of CEP170B and reduce the growth of cancer cells.

Another strategy for targeting CEP170B is to use antibodies that can specifically bind to its target. A study by the journal Cancer found that an antibody against CEP170B was able to block its activity in cancer cells and reduce the growth of cancer cells.

Biomarker potential of CEP170B:

In addition to its potential as a drug target, CEP170B has also been identified as a potential biomarker for cancer treatment. A study by the journal Biochimica et Biophysica Acta found that CEP170B was overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. The authors suggested that measuring the expression of CEP170B could be a useful biomarker for cancer diagnosis and treatment.

Conclusion:

CEP170B has been identified as a potential drug target and biomarker for cancer treatment. Its association with various cellular processes, including cell adhesion, migration, and invasion, makes it an attractive target for cancer treatment. Several studies have shown that CEP170B can be inhibited using small molecules and antibodies, making it a promising target for cancer treatment. Further research is needed to determine its full potential as a drug and biomarker for cancer treatment.

Protein Name: Centrosomal Protein 170B

Functions: Plays a role in microtubule organization

The "CEP170B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP170B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets